Related changes

Jump to: navigation, search

Enter a page name to see changes on pages linked to or from that page. (To see members of a category, enter Category:Name of category). Changes to pages on your Watchlist are in bold.

Recent changes options
Legend:
N
This edit created a new page (also see list of new pages)
m
This is a minor edit
b
This edit was performed by a bot
(±123)
The page size changed by this number of bytes
Show last 50 | 100 | 250 | 500 changes in last 1 | 3 | 7 | 14 | 30 days
Hide registered users | Hide anonymous users | Hide my edits | Show bots | Hide minor edits
Show new changes starting from 00:39, 11 May 2021
   
Page name:

10 May 2021

 m   16:32  Ofatumumab (Arzerra)‎ (diff | hist) . . (+540). . Jwarner (talk | contribs)

9 May 2021

 m   15:36  Carboplatin (Paraplatin)‎ (diff | hist) . . (+51). . Jwarner (talk | contribs) (History of changes in FDA indication)
 m   15:29  Gemcitabine (Gemzar)‎ (diff | hist) . . (+29). . Jwarner (talk | contribs) (Ovarian cancer)

8 May 2021

 m   08:55  Everolimus (Afinitor)‎ (diff | hist) . . (+5). . Jwarner (talk | contribs) (Tuberous sclerosis complex-associated renal angiomyolipoma)

7 May 2021

 m   21:33  Pembrolizumab (Keytruda)‎ (diff | hist) . . (0). . Jwarner (talk | contribs) (Non-small cell lung cancer)

6 May 2021

 m   13:26  Everolimus (Afinitor)‎ (diff | hist) . . (+445). . Jwarner (talk | contribs)
 m   08:29  Brentuximab vedotin (Adcetris)‎ (diff | hist) . . (+128). . Jwarner (talk | contribs) (History of changes in FDA indication)

5 May 2021

 m   20:14  Pembrolizumab (Keytruda)‎ (diff | hist) . . (+387). . Jwarner (talk | contribs) (Gastric or gastroesophageal junction adenocarcinoma)